

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM735501

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF TRADEMARK SECURITY INTERESTS (REEL/FRA 6955/0481)		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Wilmington Savings Fund Society, FSB, as Second Lien Collateral Agent		06/16/2022	Bank: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Mallinckrodt Pharmaceuticals Ireland Limited		
<b>Street Address:</b>	College Business & Technology Park Cruiserath		
<b>City:</b>	Blanchardstown, Dublin 15		
<b>State/Country:</b>	IRELAND		
<b>Entity Type:</b>	Private Unlimited Company: IRELAND		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	6056868	SONORANT	
<b>Serial Number:</b>	88464881	S SONORANT THERAPEUTICS	
<b>Serial Number:</b>	88464893	S SONORANT THERAPEUTICS	
<b>Serial Number:</b>	88464898	S	
<b>Serial Number:</b>	88464907	S	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	800-494-5225		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Stewart Walsh		
<b>Address Line 1:</b>	1025 Connecticut Ave NW, Suite 712		
<b>Address Line 2:</b>	COGENCY GLOBAL Inc.		
<b>Address Line 4:</b>	Washington, D.C. 20036		
<b>ATTORNEY DOCKET NUMBER:</b>	1711949 TM Rel Supp		
<b>NAME OF SUBMITTER:</b>	Jordana Dreyfuss		
<b>SIGNATURE:</b>	/Jordana Dreyfuss/		
<b>DATE SIGNED:</b>	06/17/2022		

OP \$140.00 6056868

**Total Attachments: 8**

source=MNK - 2L Notes - Trademark Release [For Filing]#page3.tif  
source=MNK - 2L Notes - Trademark Release [For Filing]#page4.tif  
source=MNK - 2L Notes - Trademark Release [For Filing]#page5.tif  
source=MNK - 2L Notes - Trademark Release [For Filing]#page6.tif  
source=MNK - 2L Notes - Trademark Release [For Filing]#page7.tif  
source=MNK - 2L Notes - Trademark Release [For Filing]#page8.tif  
source=MNK - 2L Notes - Trademark Release [For Filing]#page9.tif  
source=MNK - 2L Notes - Trademark Release [For Filing]#page10.tif

RELEASE OF TRADEMARK SECURITY INTERESTS, dated as of June 16, 2022 (this “Release”), by Wilmington Savings Fund Society, FSB, as second lien collateral agent under the Indenture (as defined below) (in such capacity, the “Second Lien Collateral Agent”) in favor of Infacare Pharmaceutical Corporation, a Delaware corporation, Ocera Therapeutics, Inc., a Delaware corporation, Mallinckrodt LLC, a Delaware limited liability company, Mallinckrodt Brand Pharmaceuticals LLC (f/k/a Mallinckrodt Brand Pharmaceuticals, Inc.), a Delaware limited liability company, Mallinckrodt ARD IP Unlimited Company (f/k/a Mallinckrodt ARD IP Limited), a private unlimited company incorporated in Ireland, Mallinckrodt Hospital Products IP Unlimited Company (f/k/a Mallinckrodt Hospital Products IP Limited), a private unlimited company incorporated in Ireland, SpecGX LLC, a Delaware limited liability company, Stratatech Corporation, a Delaware corporation, Vtesse LLC (f/k/a Vtesse Inc.), a Delaware limited liability company, and Mallinckrodt Pharmaceuticals Ireland Limited, a private limited company incorporated in Ireland (each a “Pledgor”, collectively the “Pledgors”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Second Lien U.S. Collateral Agreement, referred to below.

A. Reference is made to (i) the Second Lien U.S. Collateral Agreement, dated as of December 6, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the “Second Lien U.S. Collateral Agreement”), among Mallinckrodt International Finance S.A., a public limited liability company (société anonyme) incorporated under the laws of the Grand Duchy of Luxembourg, (the “Issuer”), Mallinckrodt CB LLC, a Delaware limited liability company (the “US Co-Issuer”, and together with the Issuer, the “Issuers”), each Guarantor listed on the signature pages thereof and each other Guarantor that becomes a party thereto after the Issue Date and the Second Lien Collateral Agent, (ii) the Notice of Grant of Security Interest in Trademarks, dated as of December 6, 2019, among the Pledgors party thereto and the Second Lien Collateral Agent, (iii) the Notice of Grant of Security Interest in Trademarks, dated as of June 2, 2020, among the Pledgor party thereto and the Second Lien Collateral Agent (such documents set forth in clauses (i) through (iii) the “Security Documents”), (iv) the Findings of Fact, Conclusions of Law, and Order Confirming Fourth Amended Joint Plan of Reorganization (With Technical Modifications) of Mallinckrodt Plc and its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code [Docket No. 6660] entered by the United States Bankruptcy Court for the District of Delaware (as amended, supplemented or otherwise modified from time to time, the “Confirmation Order”) confirming the Fourth Amended Joint Plan of Reorganization (With Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code [Docket No. 6510] (as amended, supplemented or otherwise modified from time to time, including by the Confirmation Order, the “Plan”) and (v) of the Indenture, dated as of December 6, 2019 (the “Indenture”), among the Issuers, the guarantors party thereto from time to time, BOKF, National Association (as successor to Wilmington Savings Fund Society, FSB), as trustee and Wilmington Savings Fund Society, FSB, as second lien collateral agent.

B. Pursuant to the Security Documents, the Pledgors granted to the Second Lien Collateral Agent, for the benefit of the Secured Parties, a security interest in all right, title

and interest of the Pledgors in, to and under, among other things, the Trademarks of the Pledgors set forth on Schedule I hereto (collectively, the “Trademark Collateral”), which security interest was recorded with the United States Patent and Trademark Office on (i) December 9, 2019 at Reel/Frame 6811/0522 and (ii) June 8, 2020 at Reel/Frame 6955/0481.

Accordingly, for good and valuable consideration, the receipt and sufficiency of the which are hereby acknowledged, in accordance with the Confirmation Order, the Plan, the Indenture and the Second Lien U.S. Collateral Agreement, the Second Lien Collateral Agent does hereby release, relinquish and discharge any and all security interests it has against the Trademark Collateral. If and to the extent that the Second Lien Collateral Agent has acquired any right, title or interest in and to the Trademark Collateral, the Second Lien Collateral Agent, without representation or warranty of any kind, hereby re-transfers, re-conveys and re-assigns such right, title or interest to the applicable Pledgor. The Second Lien Collateral Agent acknowledges and agrees that the Issuers or their designees shall, on behalf of the Collateral Agent (at the Issuers’ sole cost and expenses), make filings, including of this Release, with the United States Patent and Trademark Office and other necessary filings to evidence the release and termination of the Second Lien Collateral Agent’s security interests in the Trademark Collateral. The Second Lien Collateral Agent agrees to take all further actions, and provide to each Pledgor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Pledgors, at the Pledgors’ sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

THIS RELEASE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK AND SHALL BE BINDING UPON THE SECOND LIEN COLLATERAL AGENT'S REPRESENTATIVES, SUCCESSORS, ASSIGNS AND TRANSFEREES.

[The remainder of this page intentionally left black]

IN WITNESS WHEREOF, the Second Lien Collateral Agent has caused this Release to be duly executed as of the day and year first above written.

WILMINGTON SAVINGS FUND SOCIETY,  
FSB, as Second Lien Collateral Agent

By: 

Name: Rays Goldsborough

Title: Vice President

[Trademark Release]

**TRADEMARK**  
**REEL: 007756 FRAME: 0129**

Schedule I

**Trademarks**

Reel/Frame 6811/0522

Trademark	Country	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
ACTHAR	US	78/649502	6/13/2005	3093264	5/16/2006	Registered	MALLINCKRODT ARD IP LIMITED
ACTHAR GEL	US	75/445831	3/6/1998	2255322	6/22/1999	Registered	MALLINCKRODT ARD IP LIMITED
ANAFRANIL	US	77/305293	10/16/2007	3507492	9/30/2008	Registered	SPECGX LLC
CELLEX	US	77/489274	6/3/2008	4026448	9/13/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
COLOR TEAL - HORIZONTAL STRIP	US	86/283,394	5/16/2014	4674634	1/20/2015	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
COLOR TEAL - CURVED STRIP	US	85/915,748	4/26/2013	4570773	7/22/2014	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
COLOR TEAL - CURVED STRIP (updated)	US	86/637344	5/21/2015	4841528	10/27/2015	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
COLOR TEAL - TOP OF TANK AND BOTTOM WAVY STRIP	US	85/915,731	4/26/2013	4536015	5/27/2014	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
COLOR TEAL - TOP OF TANK AND TOP & BOTTOM WAVY STRIP	US	86/283,412	5/16/2014	4674635	1/20/2015	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
COLOR TEAL - TOP PROTECTOR/HAND LE	US	86/283,424	5/16/2014	4706982	3/24/2015	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
DCI	US	73/835291	11/1/1989	1599185	6/5/1990	Registered	SPECGX LLC
DSIR	US	85/070,932	6/24/2010	4003732	7/26/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
EXALGO	US	87/542359	7/25/2017	5406796	2/20/2018	Registered	SPECGX LLC
FLEXTRANET	US	86/062,864	9/12/2013	4536715		Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
FLOWMOR	US	76/386540	3/21/2002	2672085	1/7/2003	Registered	SPECGX LLC
FLOWMOR (STYLIZED)	US	75/197784	11/13/1996	2234829	3/23/1999	Registered	SPECGX LLC

Trademark	Country	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
H.P. ACTHAR GEL	US	88/017262	6/27/2018	5695589	3/12/2019	Registered	MALLINCKRODT ARD IP LIMITED
INOCAL	US	75/124,073	6/24/1996	2109970	10/28/1997	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
INOCAL CADDY	US	85/791,544	11/30/2012	4389669	8/20/2013	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
INOMAX	US	75/342495	8/18/1997	2185947	9/1/1998	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
INOMAX DSIR	US	85/071349	6/25/2010	4003735	7/26/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
INOMAX TOTAL CARE	US	85/737439	9/25/2012	4389579	8/20/2013	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
INOPULSE	US	85/031549	5/6/2010	3893703	12/21/2010	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
INOTHERAPY	US	75/751044	6/24/1999	2678500	1/21/2003	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
INOVENT	US	75/124072	6/24/1996	2100392	9/23/1997	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
LUNG LOGO (Know Sarcoidosis)	US	87/082377	6/23/2016	5129069	1/24/2017	Registered	MALLINCKRODT ARD IP LIMITED
M in box - stylized	US	75/669100	3/26/1999	2332279	3/21/2000	Registered	MALLINCKRODT LLC
MALLINCKRODT	US	72/296373	4/24/1968	884412	1/20/1970	Registered	MALLINCKRODT BRAND PHARMACEUTICA LS, INC. (assignment to Mallinckrodt Enterprises LLC not yet recorded; subsequent assignment will be needed

Trademark	Country	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
MALLINCKRODT	US	73/525945	3/8/1985	1410012	9/23/1986	Registered	MALLINCKRODT BRAND PHARMACEUTICALS, INC. (assignment to Mallinckrodt Enterprises LLC not yet recorded; subsequent assignment will be needed)
MALLINCKRODT w/ CUBE logo	US	85/646924	6/8/2012	5036705	9/6/2016	Registered	MALLINCKRODT BRAND PHARMACEUTICALS, INC. (assignment to Mallinckrodt Enterprises LLC not yet recorded; subsequent assignment will be needed)
MALLINCKRODT w/ CUBE logo In Color (Version 2)	US	85/845125	2/8/2013	4641807	11/18/2014	Registered	MALLINCKRODT BRAND PHARMACEUTICALS, INC. (assignment to Mallinckrodt Enterprises LLC not yet recorded; subsequent assignment will be needed)
METHADOSE	US	72/409510	12/6/1971	958455	5/8/1973	Registered	SPECGX LLC
METHYLIN	US	75/551811	9/11/1998	2398488	10/24/2000	Registered	SPECGX LLC
NICU-PET	US	85/836260	1/30/2013	4410417	10/1/2013	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
NIKS	US	75/928861	2/26/2000	3312981	10/16/2007	Registered	STRATATECH CORPORATION
OCERA	US	78/968521	9/6/2006	5438448	4/3/2018	Registered	OCERA THERAPEUTICS, INC.
OCERA	US	78/756637	11/17/2005	4790741	8/11/2015	Registered	OCERA THERAPEUTICS, INC.
OFIRMEV	US	77/857487	10/26/2009	3955489	5/3/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
PAMELOR	US	72/350038	1/30/1970	906503	1/26/1971	Registered	SPECGX LLC
PARZONE	US	72/002436	2/10/1956	636736	11/6/1956	Registered	SPECGX LLC



Trademark	Country	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
QUESTCOR AND DESIGN	US	75/867216	12/9/1999	2756559	8/26/2003	Registered	QUESTCOR PHARMACEUTICALS, INC. (assignment to Mallinckrodt ARD IP Limited not recorded; do not intend to renew)
RESTORIL	US	73/058683	7/25/1975	1038108	4/20/1976	Registered	SPECGX LLC
ROXICODONE	US	76/401917	4/24/2002	2686302	2/11/2003	Registered	SPECGX LLC
STANATE	US	76/408361	5/15/2002	2851513	6/8/2004	Registered	INFACARE PHARMACEUTICAL CORPORATION (assignment to Mallinckrodt Hospital Products IP Limited not recorded; do not intend to renew)
STRATAGRAFT	US	78/540747	1/1/2005	3395813	3/11/2008	Registered	STRATATECH CORPORATION
STRATATECH	US	77/088429	1/22/2007	3342834	11/27/2007	Registered	STRATATECH CORPORATION
TERLIVAZ	US	85/876469	3/14/2013	4720688	4/14/2015	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
THERAKOS	US	77/489277	6/3/2008	4115195	3/20/2012	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
TOFRANIL	US	87/543724	7/26/2017	5406873	2/20/2018	Registered	SPECGX LLC
UVADEX	US	85/319332	5/12/2011	4074104	12/20/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
UVADEX	US	77/489275	6/3/2008	4006506	8/2/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
UVAR	US	77/489273	6/3/2008	3908397	1/18/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
UVAR XTS	US	77/948145	3/2/2010	3949903	4/26/2011	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
V DOT LOGO (Ofirmev)	US	85/672800	7/10/2012	4433497	11/12/2013	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
XARTEMIS	US	85/705518	8/16/2012	4632837	11/4/2014	Registered	MALLINCKRODT LLC

Trademark	Country	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Owner
YIN-YANG DESIGN (black & white version)	US	86/694083	7/15/2015	4940208	4/19/2016	Registered	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED

Reel/Frame 6955/0481

### U.S. Trademark Registrations

Mark	Registration No.	Registration Date	Owner
Sonorant	6056868	05/19/2020	Mallinckrodt Pharmaceuticals Ireland Limited

### U.S. Trademark Applications

Mark	Application No.	Filing Date	Owner
Sonorant Therapeutics with S Logo (color)	88/464881	06/07/2019	Mallinckrodt Pharmaceuticals Ireland Limited
Sonorant Therapeutics with S Logo (black & white)	88/464893	06/07/2019	Mallinckrodt Pharmaceuticals Ireland Limited
S Logo (color)	88/464898	06/07/2019	Mallinckrodt Pharmaceuticals Ireland Limited
S Logo (black & white)	88/464907	06/07/2019	Mallinckrodt Pharmaceuticals Ireland Limited